Lanifibranor

生产企业：Inventiva

Lanifibranor is under investigation in clinical trial NCT03008070 (Phase 2b Study in NASH to Assess IVA337).

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Lanifibranor is under investigation in clinical trial NCT03008070 (Phase 2b Study in NASH to Assess IVA337).

作用机制

Pan-PPAR agonist

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

CRYSTAL FORM OF LANIFIBRANOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
- US 2022402906 A1
  申请人: CRYSTAL PHARMACEUTICAL SUZHOU CO LTD优先权: 2020
  US
  WO
  6 件公开
- EP 4385990 A4
  申请人: INVENTIVA优先权: 2021
  CN
  EP
  US
  WO
  5 件公开
CRYSTALLINE FORM OF LANIFIBRANOR
EP 4504725 A1申请人: INVENTIVA优先权: 2022
EP
US
WO
3 件公开
METHOD OF MAKING LANIFIBRANOR
EP 4780541 A1申请人: INVENTIVA优先权: 2023
EP
US
WO
3 件公开
SOLID STATE FORMS OF LANIFIBRANOR AND PROCESS FOR PREPARATION THEREOF
EP 4352056 A1申请人: TEVA PHARMACEUTICALS INT GMBH优先权: 2021
EP
US
3 件公开
NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT
- US 2024408069 A1
  申请人: INVENTIVA优先权: 2023
  US
  WO
  3 件公开
- US 2024410904 A1
  申请人: INVENTIVA优先权: 2023
  US
  WO
  3 件公开
COMBINATION THERAPY FOR THE TREATMENT OF A LIVER DISEASE
EP 4000616 A1申请人: INVENTIVA优先权: 2020
EP
US
2 件公开
LANIFIBRANOR FOR USE IN THE TREATMENT OF SPLANCHNIC VASODILATATION IN A PATIENT WITH A LIVER CONDITION
EP 4719380 A1申请人: INVENTIVA优先权: 2023
EP
WO
2 件公开
SYNTHESIS OF LANIFIBRANOR INTERMEDIATE
EP 4750772 A1申请人: INVENTIVA优先权: 2023
EP
WO
2 件公开
COMBINATION THERAPY FOR THE PREVENTION AND/OR THE TREATMENT OF A LIVER DISEASE
- WO 2025132955 A1
  申请人: INVENTIVA优先权: 2023
  CN
  WO
  2 件公开
- WO 2025132989 A1
  申请人: INVENTIVA优先权: 2023
  CN
  WO
  2 件公开
SYNTHESIS OF LANIFIBRANOR
- EP 4759808 A1
  申请人: INVENTIVA优先权: 2024
  EP
  WO
  2 件公开
- EP 4759809 A1
  申请人: INVENTIVA优先权: 2024
  EP
  WO
  2 件公开

药物

Lanifibranor

概览

作用机制

相关疾病

专利

CRYSTAL FORM OF LANIFIBRANOR, PREPARATION METHOD THEREFOR, AND USE THEREOF

NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT

COMBINATION THERAPY FOR THE PREVENTION AND/OR THE TREATMENT OF A LIVER DISEASE

SYNTHESIS OF LANIFIBRANOR